The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | The rationale & objectives of the PedAL master trial: improving pediatric oncology drug development
In this interview, Gwen Nichols, MD, The Leukemia & Lymphoma Society, Rye Brook, NY, briefly highlights the rationale behind the Pediatric Acute Leukemia (PedAL) master trial (NCT04726241), which aims to accelerate pediatric drug development in acute leukemias and improve the outcomes of children with these malignancies. Enrollment begins with the PedAL screening trial, which uses clinical and biological characteristics of acute leukemias to screen for patient eligibility for available Phase I/II sub-trials. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Maybe I’ll start with the objective first. What we realized is that pediatric drug development, particularly in oncology, has not benefited from all of the science in the same way that adult oncology has. Some of that is because, thankfully, pediatric tumors, in particular pediatric leukemias, are rare compared with those in adults. But the backward thinking on this is that a six-year-old has so many more years of life and so much more benefit from being saved than a 60-year-old does, and I can say that because I have enough gray hair to say that, that we really need to rethink how we develop therapies in oncology for children...
Maybe I’ll start with the objective first. What we realized is that pediatric drug development, particularly in oncology, has not benefited from all of the science in the same way that adult oncology has. Some of that is because, thankfully, pediatric tumors, in particular pediatric leukemias, are rare compared with those in adults. But the backward thinking on this is that a six-year-old has so many more years of life and so much more benefit from being saved than a 60-year-old does, and I can say that because I have enough gray hair to say that, that we really need to rethink how we develop therapies in oncology for children. And that’s why PedAL was started, to find more efficient ways to bypass the roadblocks that we see in pediatric oncology drug development.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
